首页/数据集/Efficacy of antiviral combination therapy for treatment of chronic HCV infection.

Efficacy of antiviral combination therapy for treatment of chronic HCV infection.

Figshare2018-02-22 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Efficacy_of_antiviral_combination_therapy_for_treatment_of_chronic_HCV_infection_/5911726 数据链接链接失效反馈

官方服务：

资源简介：

Efficacy of antiviral combination therapy for treatment of chronic HCV infection.

应用场景：

创建时间：

2018-02-22

丙型肝炎治疗

T细胞免疫重建

We analyzed hepatitis C virus (HCV)-specific T cells and non-specific memory T cell populations from 6 patients with chronic HCV infection receiving 12 weeks of direct-acting antiviral (DAA) therapy w

NIAID Data Ecosystem80

丙型肝炎治疗

直接抗病毒药物荟萃分析

This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: - Supplementary figure 1: Thematic map

NIAID Data Ecosystem50

Reasons for discontinuation of telaprevir and incidence of the most common AEs and Grade 3–4 AEs during the telaprevir phase in the intent-to-treat population.

药物不良反应监测

丙型肝炎治疗

* Includes six F0–F2 patients.† Listed are drug-related AEs that occurred in at least 5% of the overall population during the telaprevir phase.‡ Included in this category are all related events that w

Figshare2015-12-03 更新40

Supplementary Material for: Serum angiopoietin-2 levels predict the development of hepatocellular carcinoma following hepatitis C virus eradication using direct-acting antiviral agents

肝细胞癌预测

丙型肝炎治疗

Introduction: Our previous studies showed that serum angiopoietin-2 (Ang-2) and C-X-C motif chemokine ligand 10 (CXCL10) levels predicted improvement in liver fibrosis following sustained virological

DataCite Commons2024-07-25 更新80

HBV infected participants on treatment.

肝炎临床治疗

抗病毒疗效评估

HBV infected participants on treatment.

NIAID Data Ecosystem50